235 related articles for article (PubMed ID: 37243127)
1. Mechanistic-Based Classification of Endocytosis-Related Inhibitors: Does It Aid in Assigning Drugs against SARS-CoV-2?
Hessien M; Donia T; Tabll AA; Adly E; Abdelhafez TH; Attia A; Alkafaas SS; Kuna L; Glasnovic M; Cosic V; Smolic R; Smolic M
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243127
[TBL] [Abstract][Full Text] [Related]
2. Insight into the role of clathrin-mediated endocytosis inhibitors in SARS-CoV-2 infection.
Alkafaas SS; Abdallah AM; Ghosh S; Loutfy SA; Elkafas SS; Abdel Fattah NF; Hessien M
Rev Med Virol; 2023 Jan; 33(1):e2403. PubMed ID: 36345157
[TBL] [Abstract][Full Text] [Related]
3. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.
Glebov OO
FEBS J; 2020 Sep; 287(17):3664-3671. PubMed ID: 32428379
[TBL] [Abstract][Full Text] [Related]
4. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
5. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
6. Identification of diphenylurea derivatives as novel endocytosis inhibitors that demonstrate broad-spectrum activity against SARS-CoV-2 and influenza A virus both in vitro and in vivo.
Kumar N; Taily IM; Singh C; Kumar S; Rajmani RS; Chakraborty D; Sharma A; Singh P; Thakur KG; Varadarajan R; Ringe RP; Banerjee P; Banerjee I
PLoS Pathog; 2023 May; 19(5):e1011358. PubMed ID: 37126530
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis.
Bayati A; Kumar R; Francis V; McPherson PS
J Biol Chem; 2021; 296():100306. PubMed ID: 33476648
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
9. Potential inhibitors of SARS-CoV-2: recent advances.
Jamalipour Soufi G; Iravani S
J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
[TBL] [Abstract][Full Text] [Related]
10. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
[TBL] [Abstract][Full Text] [Related]
11. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
[TBL] [Abstract][Full Text] [Related]
12. Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.
Boytz R; Słabicki M; Ramaswamy S; Patten JJ; Zou C; Meng C; Hurst BL; Wang J; Nowak RP; Yang PL; Sattler M; Stone RM; Griffin JD; Gray NS; Gummuluru S; Davey RA; Weisberg E
J Med Virol; 2023 Jan; 95(1):e28157. PubMed ID: 36117402
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
14. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
[TBL] [Abstract][Full Text] [Related]
15.
Gurung AB
Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
[TBL] [Abstract][Full Text] [Related]
16. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway.
Wang H; Yang P; Liu K; Guo F; Zhang Y; Zhang G; Jiang C
Cell Res; 2008 Feb; 18(2):290-301. PubMed ID: 18227861
[TBL] [Abstract][Full Text] [Related]
17. Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection.
Aslam M; Ladilov Y
Cells; 2020 Aug; 9(9):. PubMed ID: 32854430
[TBL] [Abstract][Full Text] [Related]
18. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
Shahbazi B; Mafakher L; Teimoori-Toolabi L
J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
[TBL] [Abstract][Full Text] [Related]
20. Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2.
Ku KB; Shin HJ; Kim HS; Kim BT; Kim SJ; Kim C
J Microbiol Biotechnol; 2020 Dec; 30(12):1843-1853. PubMed ID: 33203821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
